MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

Sofinnova Partners appoints David Evans as Partner

Inventiva Strengthens Board of Directors with Appointment of Three Distinguished Life Sciences Leaders

Abivax Announces Closing of $920 Million Public Offering

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. 

Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here. 

